EditorialTheEUGOGOConsensusStatementontheManagementofGraves'Orbitopathy:EquallyApplicabletoNorthAmericanCliniciansandPatientsTheEuropeangrouponGraves'orbitopathy(EUGOGO;www.
eugogo.
org)isamultidisciplinaryconsortiumofclinicianscommittedtoimprovingtheman-agementofpatientswiththeocularcomplicationsofGraves'disease.
ThegroupdevelopedaconsensusstatementonthemanagementofGraves'orbitopathy(GO)thatwasunveiledattheannualmeetingoftheEuropeanThyroidAssociationinLeipzig,Germany,inSeptember2007,andsimultane-ouslyappearsinthisissueofThyroidandintheEuropeanJournalofEndocrinology(1).
EUGOGOistobecommendedfortheireffortsthatreectaremarkabledegreeofinterna-tionalcooperationbyacademicendocrinologistsandoph-thalmologists.
Theauthorsrefertothedocumentasa''consensusstate-ment''byexpertsintheeld,ratherthanapracticeguideline.
Thisseemsappropriate,becausewhiletheEUGOGOgroupcanbecreditedwithhavingperformedthemajorityofran-domizedcontrolledtrials(RCTs)inthisarea,theyarenotofsufcientscopetosupportformalpracticeguidelines.
De-spitethis,thedocumentistimelyandshouldproveusefultoclinicianswhomanageGOpatients.
Theauthorsrightlyanticipatethatthedocumentwill''provideafocusforauditandresearch''andaidintheidenticationoftopicsforfutureRCTs.
Theconsensusstatementisscholarlyandconcise,andtherecommendationsaregenerallyapplicabletoNorthAmeri-can,aswellasEuropean,cliniciansandpatients.
Thegradedrecommendationsareappendedinthedocument,andtheevidencesupportingeachisdiscussedindetailinthebodyofthetext.
TheapplicationoftherecommendationsrequiresthatcliniciansmustrstsegregatetheirGOpatientsinto''mild,''''moderatetosevere,''or''sight-threatening''categories,anddeterminewhetherornotthediseaseisactive.
Sufcientde-tailsareprovidedwithinthetextregardingtheassessmentofdiseaseseverityandactivitytoallowclassicationintothesebroadcategories.
EUGOGOdoesnotadvocateusinganyde-tailedgradingorscoringsystemotherthantherelativelysimple''clinicalactivityscore''andspecicocularmeasure-mentstoassesstheseverityofthedisease.
Whilethisapproachmaynotideallycaptureallfeaturesofthedisease,ithasbeenvalidatedbythegroupinnumerousclinicalstudiesandshouldserveasthegoldstandardagainstwhichotherGOclassica-tionsystemsaremeasured.
ThedocumentwillserveasanespeciallyusefultoolforclinicianswhoalreadyhavesomeexpertiseinmanagingGOpatients.
OthersnotsoexperiencedbutencounterGOpa-tientsintheirpracticeareadvisedto''referpatientswithGO,exceptforthemildestcases,tocombinedthyroid–eyeclinicsforfurtherassessmentandmanagement.
''Whichreferralsshouldbemadeurgentlyandwhicharenonurgentiscare-fullyoutlinedinthetext.
TheproblematicaspectofthisrecommendationforcliniciansinNorthAmerica,however,isthatregionalGOconsultantsarefrequentlyophthalmolo-gistswhodonotworkincombinedthyroid–eyeclinics.
OneofthemanypositiveresultsstemmingfromtheinceptionofEUGOGOhasbeenthemandatoryestablishmentofacom-binedthyroid–eyeclinicwithineachoftheEuropeanmedicalcenterwishingtoparticipateintheconsortium.
OnlythroughthistypeofcooperationcanGOpatientsbenetfromthefullrangeofexpertiseneededtounderstandandmanageallaspectsofthisperplexingdisease.
Whilethevastmajorityoftherecommendationsseemtometobequitereasonableandbasedtotheextentpossibleonpertinentliterature,Idotakeissuewiththestatementthat''thetreatmentofchoiceformoderatetosevereandactiveGOispulsesofintravenousglucocorticoids(GCs).
''WhilesevereGOmaywarrantthisapproach,IremainreluctanttorecommendivGCstopatientswithonlymoderatedisease(i.
e.
,thosehavingonlyasinglefeaturethatwouldplacetheminthe''moderatetosevere''category,orafewfeaturesmeasuringjustabovemild).
MyconcernstemsbothfromreportsoffatalacuteliverfailureinfourGOpatientsduringorfollowingcompletionofivGCtreatment(2,3),andfromthenaturalhistoryofthediseaseshowingimprovementinthemajorityof(albeitunselected)patientswithinayears'time.
Fortunately,thefrequencyofhepatotoxicityappearstobeverylow;7ofapproximately800GOpatientstreatedinItalywithivGCssufferedsevereliverdamage,ofwhom3died(3).
BecausenocaseofliverfailurehasbeenreportedinGOpatientsreceiving<8gmethylprednisolone,thecon-sensusstatementindicatesthatthecumulativedoseinonecourseshouldbelessthanthisamountandspeciesthativGCsshouldonlybeadministeredincentersexperiencedinthistherapy.
Despitethis,therisk–benetratioforivGCsinpatientswithactivediseaseofonlymoderateseveritywhomightdoequallywellwithoralsteroidsorevencarefulTHYROIDVolume18,Number3,2008MaryAnnLiebert,Inc.
DOI:10.
1089=thy.
2008.
0034281observationandfrequentreassessmentseemstometobeweightedtowardthesideofunacceptablerisk.
Insummary,theconsensusstatementbyEUGOGOisatimelyandusefuldocumentthatcanbeupdatedasadditio-nalevidencefromfutureRCTsbecomesavailable.
TheEu-ropeangroupisproceedingwithmulticentertrialsthatwillallowrecruitmentoflargenumbersofpatientsintothesestudies.
Thisconsensusstatementbringstotheforeashort-cominginthecareofGOpatientsintheUnitedStates,namely,thatmanypatientsarenotcaredforinjointthyroid–eyeclinics.
Inaddition,endocrinologists,ophthalmologists,andotherswhoseeGOpatientsinthiscountryarenotyetorganizedtoperformmulticenterRCTs.
Thereis,how-ever,activityunderwaytoincreasecooperationbetweenthesegroupsandtoestablishtheimportantinfrastructureneededtoperformlargemulticenterGOtrialsinNorthAmerica.
Finally,whileevidence-basedguidelinesorconsensusstatementscanfacilitatedecisionmaking,managementmustbeultimatelyindividualizedandfocusedontheneedsanddesiresofthepatient.
Thisrequirestheapplicationofboththeartandscienceofmedicine,anddemandsthatthecli-nicianactivelylistenstoGOpatients,manyofwhomareunderstandablyapprehensiveandfrightened.
Compassio-natecounselingofpatientshouldincludewiderangingdis-cussionsonthenatureoftheconditionanditsnaturalhistory,aswellascustomizedtreatmentoptions.
Suchanapproachislikelytoimproveoutcomesofwhatisoftenahighlydistressingdisease.
References1.
BartalenaL,BaldeschiL,DickensonA,EcksteinA,Kendall-TaylorP,MarcocciC,etal.
2007ConsensusstatementoftheEuropeanGrouponGraves'Orbitopathy(EUGOGO)onthemanagementofGraves'orbitopathy.
Thyroid18:333–346.
2.
WeisselM,HauffW2000Acuteandfatalliverfailureafterhigh-doseglucocorticoidpulsetherapyinapatientswithsevereeyedisease.
Thyroid10:521.
3.
MarinoM,MorabitoBrunetteMR,BartalenaL,PincheraA,MarcocciC2004AcuteandsevereliverdamageassociatedwithintravenousglucocorticoidpulsetherapyinpatientswithGraves'ophthalmopathy.
Thyroid14:403–406.
—RebeccaBahn,M.
D.
President,AmericanThyroidAssociationConsultantinEndocrinology,MayoClinic282BAHN
妮妮云的来历妮妮云是 789 陈总 张总 三方共同投资建立的网站 本着“良心 便宜 稳定”的初衷 为小白用户避免被坑妮妮云的市场定位妮妮云主要代理市场稳定速度的云服务器产品,避免新手购买云服务器的时候众多商家不知道如何选择,妮妮云就帮你选择好了产品,无需承担购买风险,不用担心出现被跑路 被诈骗的情况。妮妮云的售后保证妮妮云退款 通过于合作商的友好协商,云服务器提供2天内全额退款,超过2天不退款 物...
pacificrack在最新的7月促销里面增加了2个更加便宜的,一个月付1.5美元,一个年付12美元,带宽都是1Gbps。整个系列都是PR-M,也就是魔方的后台管理。2G内存起步的支持Windows 7、10、Server 2003\2008\2012\2016\2019以及常规版本的Linux!官方网站:https://pacificrack.com支持PayPal、支付宝等方式付款7月秒杀VP...
Vultr 商家有新增韩国首尔机房,这个是继日本、新加坡之后的第三个亚洲机房。不过可以大概率知道肯定不是直连中国机房的,因为早期的日本机房有过直连后来取消的。今天准备体验看看VULTR VPS主机商的韩国首尔机房的云服务器的速度和性能。1、全球节点PING速度测试这里先通过PING测试工具看看全球几十个节点的PING速度。看到好像移动速度还不错。2、路由去程测试测试看看VULTR韩国首尔机房的节点...
www.gogo.com为你推荐
brandoff香港购物在哪里同ip网站查询我的两个网站在同一个IP下,没被百度收录,用同IP站点查询工具查询时也找不到我的网站,是何原因?月神谭给点人妖。变身类得小说。www.175qq.com最炫的qq分组www.147.qqq.com谁有147清晰的视频?学习学习www.mfav.org邪恶动态图587期 www.zqzj.orghao.rising.cn我一打开网页就是瑞星安全网站导航,怎么修改?朴容熙这个女的叫什么?本冈一郎只想问本冈一郎的效果真的和说的一样吗?大概多长时间可以管用呢?用过的进!铂金血痕仇家血痕是个成语吗?
虚拟主机软件 台湾虚拟主机 香港服务器租用 欧洲免费vps 域名备案号查询 plesk 12u机柜尺寸 eq2 hnyd 域名转接 国外免费asp空间 台湾谷歌 国外视频网站有哪些 512mb 智能dns解析 贵阳电信测速 工信部网站备案查询 华为k3 免费获得q币 月付空间 更多